INSIGHT-003 investigator-initiated trial - 1st patient dosed
Filed with ASX · · 2 pages · English
SYDNEY, AUSTRALIA–5 August 2021–Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”or the “Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that the first patient has been enrolled and safely dosed in INSIGHT-003. This patient with metastatic non-small cell lung carcinoma received pembrolizumab plus
Earlier from Immutep
- Completion of Placement - Tranche 2
- Completion of Share Purchase Plan
- US FDA & IRB approves start of ph2b head & neck cancer trial
- Efti to be evaluated in new triple combination therapy trial
- Immutep secures commitments for A$60 million in a Placement
Later from Immutep
- Chinese patent granted for anti-LAG-3 antibody LAG525
- Immuteps partner, EOC Pharma, expands efti trial pipeline
- Recruitment of patients completed for Part B of TACTI-002
- Immutep Receives A$3.4 million R&D French Tax Incentive
- Immutep Quarterly Activities Report & Appendix 4C
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep